Can New Generation GLP-1s Overcome The Adherence Hurdle?

Historically, Patients Have Not Tended To Stay On These Drugs Long-Term

 
• By Chloe Kent
  
Pair of hands holding semaglutide injection pen
Patients taking Wegovy lost an average of 15.2% of their body weight in clinical trials • Source: Shutterstock
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Intelligence

More from In Vivo